The proposed anti-tumor mechanisms of RAS inhibitors include suppression of angiotensin II-mediated tumor neovascularization, inhibition of cellular proliferation signaling pathways, and attenuation of metastatic potential. This evidence concerns the gene AGT and neoplasm.